Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 14/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.54 |
| ▸ | HPN | P05981 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elsibucol SCHEMBL6002307 | 0.88 | VCAM1 (0.73) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL13609378 | 0.88 | VCAM1 (0.60) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL8353439 | 0.87 | VCAM1 (0.90) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL14037559 | 0.84 | VCAM1 (0.70) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL12042598 | 0.82 | ALOX15 (0.62) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL14586319 | 0.81 | VCAM1 (0.67) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL12042599 | 0.81 | ALOX15 (0.60) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL5575964 | 0.81 | ALOX15 (0.64) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL8243913 | 0.80 | ALOX15 (0.58) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL6054982 | 0.80 | VCAM1 (0.92) | VCAM1ALOX15HPNMAPTSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189581-A1 | Compounds and methods for treating transplant rejection | ATHEROGENICS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-7087645-B2 | Compounds and methods for treating transplant rejection | ATHEROGENICS, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040138147-A1 | Compounds and methods for treating transplant rejection | ATHEROGENICS, INC. | 2004-07-15 | — | — | US | disclosed |
| US-6670398-B2 | Assymetric derivatives of 2,2-bis(p-hydroxyphenylthio)propane | ATHEROGENICS, INC. | 2003-12-30 | — | — | US | disclosed |
| US-20030153536-A1 | Phenylthioalkane compounds | GLASS MITCHELL (US) | 2003-08-14 | — | — | US | disclosed |
| US-20020156022-A1 | Compounds and methods for treating transplant rejection | CRABTREE ACQUISITION CO, LLC | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156022-A1 | Compounds and methods for treating transplant rejection | CD74, HLA-B, HLA-C | VCAM1 905/4885ALOX15 402/4885HPN 3143/4885 |
| US-20060189581-A1 | Compounds and methods for treating transplant rejection | HLA-B, HLA-C, CD74 | VCAM1 1475/4885ALOX15 481/4885HPN 2501/4885 |
| US-20030153536-A1 | Phenylthioalkane compounds | PBK, TST, NAT1 | VCAM1 708/4885ALOX15 870/4885HPN 3313/4885 |
| US-20040138147-A1 | Compounds and methods for treating transplant rejection | CD74, HLA-B, HLA-C | VCAM1 905/4885ALOX15 402/4885HPN 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.